Alkem Laboratories Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ah65d1aau66u2lwtmfojw8l8.pdf

Key Takeaways


India Business: Market Leadership and Outperformance

Vikas Gupta: "I have always maintained that we will continue to outperform the market at least by 100 to 150 basis points."

U.S. Business: Launch-Dependent Growth with Price Erosion Risk

Vikas Gupta: "price erosion in a new launch in U.S. is a market phenomenon, right? This is only first quarter of players entering. So the question is whether price erosion will happen, price erosion will happen. But when it starts tracking, whether it is 3 months from now, 6 months from now, we'll wait and see."

CDMO: Early Days with a Defined Ramp Path

Vikas Gupta: "we see a good opportunity in that business. And at this stage, because we've just made the plant operational, first, we would like to maximize the output of this plant. But say, 3 to 6 months down the line, if we see an opportunity and if that warrants us to make and scale up that business and make further investments, we won't shy away."

Margins: H1 Strength, H2 Absorption

Vikas Gupta: "I've always maintained that year-on-year, we should look at least a 1% improvement in our overall margins. And I think we are pretty much on track for that."

International and New Ventures: Diversification in Motion

Vikas Gupta: "We will be a meaningful player over there... I'm sure everybody would be inking it's a pretty large opportunity, and I'm sure there is room for meaningful presence for more than one player in that market."

Guidance & Commitments

CommitmentSpecificsTimeline
India growth outperformanceOutperform IPM by at least 100 to 150 bps; double-digit growth assuming market grows at 8% to 8.5%FY26 and FY27
Full-year EBITDA margin19.5% to 20%FY26
U.S. revenue growthLow double-digit, around 10% to 11%FY26
Non-U.S. revenue growthHigh teens, upwards of close to 20%FY26
U.S. CDMO revenueClose between ₹70 to 80 croresFY26
U.S. CDMO annual run rate₹300 crores from current production capacityNext 12 to 18 months
U.S. CDMO breakevenPlant reaches breakeven12 to 18 months
R&D spendWithin 4% to 5% of revenueFY26
H2 other expenses (quarterly)Around ₹900 to 905 crores including Enzene and MedtechQ3 and Q4 FY26
Sikkim GST impact run-rate₹25 to 30 crores per quarterOngoing from H2 FY26
Effective tax rate35% to 38% as company exits MAT after March 2026FY27
Medium-term margin expansionAt least 1 percentage point year-on-year improvementFY27 onwards
Medtech breakevenBusiness reaches breakevenFY28
Tolvaptan (Jynarque) launchLaunch after litigation resolutionFY27-28
U.S. H2 launchesAt least 3 or 4 more launchesH2 FY26

Key Metrics

MetricQ2 FY26
Revenue from operations₹4,001 cr, all-time high, +17.2% YoY
India sales₹2,766 cr, +12.4% YoY
U.S. sales₹764.9 cr, +28% YoY
Non-U.S. sales₹424.1 cr, +32.4% YoY
EBITDA₹920.8 cr, +22.3% YoY; margin 23%
Net profit after minority interest₹765.1 cr, +11.1% YoY
R&D expenses₹130.2 cr, 3.3% of total revenue
Gross margin65% in Q2; 64% to 65% expected for H2 and full year
Full-year EBITDA margin guidance19.5% to 20%
India business growth outlook100 to 150 bps above IPM growth, sustained outperformance expected
U.S. business full-year growth expectation10% to 11%, low double-digit, up from earlier mid-single-digit expectation
Non-U.S. constant currency growth~28% (per an analyst's math), with currency gain of 4% to 4.5%
Enzene U.S. CDMO revenue booked so far₹40 cr to ₹45 cr; ~₹20 cr per quarter expected for next 2 quarters
Enzene U.S. CDMO annual run rate target₹300 cr, expected in next 12 to 18 months
Enzene U.S. CDMO opex per quarter~₹50 cr, starting Q3 FY26
GST impact from loss of Sikkim benefit₹50 cr to ₹60 cr in H2 FY26; ~₹25 cr to ₹30 cr per quarter
GST one-time trade arrangement impact₹10 cr to ₹12 cr
Medtech revenue~₹2.5 cr (900 knee replacements)
Medtech opex and EBITDA lossOpex ₹8 cr to ₹9 cr; EBITDA loss ~₹5.5 cr
Adroit revenue run rate~₹15 cr for the quarter, at breakeven
U.S. launches in H1 FY264 launches; sacubitril/valsartan most meaningful
U.S. launches planned for H2 FY26At least 3 to 4 more
Effective tax rate expectation for FY2735% to 38%
MAT credit on balance sheetMore than ₹1,500 cr; no significant cash outflow for next 1 to 2 years
Other expenses expected for Q3 and Q4 FY26~₹900 cr to ₹905 cr per quarter, including Enzene and Medtech